Related references
Note: Only part of the references are listed.Therapeutic goals in the treatment of Fabry disease
Atul Mehta et al.
GENETICS IN MEDICINE (2010)
Four-Year Prospective Clinical Trial of Agalsidase Alfa in Children with Fabry Disease
Raphael Schiffmann et al.
JOURNAL OF PEDIATRICS (2010)
Baseline characteristics of patients enrolled in the Canadian Fabry Disease Initiative
S. Sirrs et al.
MOLECULAR GENETICS AND METABOLISM (2010)
A validated disease severity scoring system for Fabry disease
Edward H. Giannini et al.
MOLECULAR GENETICS AND METABOLISM (2010)
End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry
Alberto Ortiz et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies
Chloe Tesmoingt et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy Evidence for a Better Outcome With Early Treatment
Frank Weidemann et al.
CIRCULATION (2009)
Fabry disease in children and the effects of enzyme replacement treatment
Guillem Pintos-Morell et al.
EUROPEAN JOURNAL OF PEDIATRICS (2009)
Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease
Jean-Claude Lubanda et al.
GENETICS IN MEDICINE (2009)
Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry
Stephen Waldek et al.
GENETICS IN MEDICINE (2009)
A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease
Catharina Whybra et al.
GENETICS IN MEDICINE (2009)
Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study
M. Imbriaco et al.
HEART (2009)
Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy
Rocio Toro et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2009)
Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey
A. Mehta et al.
JOURNAL OF MEDICAL GENETICS (2009)
Agalsidase Alfa and Kidney Dysfunction in Fabry Disease
Michael West et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data
A. Mehta et al.
LANCET (2009)
A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry disease
Bernard Benichou et al.
MOLECULAR GENETICS AND METABOLISM (2009)
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
Raphael Schiffmann et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2009)
Stroke in Fabry Disease Frequently Occurs Before Diagnosis and in the Absence of Other Clinical Events Natural History Data From the Fabry Registry
Katherine Sims et al.
STROKE (2009)
Cardiac manifestations of Anderson-Fabry disease in children and adolescents
Christoph Kampmann et al.
ACTA PAEDIATRICA (2008)
Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria
Camilla Tondel et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)
Skin-impedance in Fabry Disease: A prospective, controlled, non-randomized clinical study
Surya N. Gupta et al.
BMC NEUROLOGY (2008)
Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson-Fabry disease: testing the effects with the Mainz Severity Score Index
R. Parini et al.
CLINICAL GENETICS (2008)
Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy
T. Kovacevic-Preradovic et al.
EUROPEAN JOURNAL OF ECHOCARDIOGRAPHY (2008)
Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa
D. A. Hughes et al.
HEART (2008)
Onset and progression of the Anderson-Fabry disease related cardiomyopathy
Christoph Kampmann et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2008)
Twenty-four-month α-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters
J. W. Koskenvuo et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2008)
Short-term efficacy of enzyme replacement therapy in Korean patients with Fabry disease
Jin-Ho Choi et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2008)
Safety and efficacy of enzyme replacement therapy with agalsidase beta: An international, open-label study in pediatric patients with Fabry disease
J. Edmond Wraith et al.
JOURNAL OF PEDIATRICS (2008)
Lysosomal storage disease 3 - Fabry's disease
Yuri A. Zarate et al.
LANCET (2008)
Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3
Anouk C. Vedder et al.
MOLECULAR GENETICS AND METABOLISM (2008)
Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
William R. Wilcox et al.
MOLECULAR GENETICS AND METABOLISM (2008)
Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy
Renzo Mignani et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy
Alberto Ortiz et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
Characterization of Fabry Disease in 352 Pediatric Patients in the Fabry Registry
Robert J. Hopkin et al.
PEDIATRIC RESEARCH (2008)
A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium
Frank Weidemann et al.
EUROPEAN HEART JOURNAL (2007)
Gastrointestinal symptoms in 342 patients with Fabry disease: Prevalence and response to enzyme replacement therapy
Bjoern Hoffmann et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy
Toya Ohashi et al.
MOLECULAR GENETICS AND METABOLISM (2007)
Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy
A. Palla et al.
JOURNAL OF NEUROLOGY (2007)
Antiproteinuric therapy and Fabry nephropathy:: Sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-β
Hindia Tahir et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg
Anouk C. Vedder et al.
PLOS ONE (2007)
Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease
Gregory M. Pastores et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2007)
Sustained, long-term renal stabilization after 54 months of agalsidase β therapy in patients with Fabry disease
Dominique P. Germain et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry
C. M. Eng et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2007)
Heart in Anderson-Fabry disease and other lysosomal storage disorders
Ales Linhart et al.
HEART (2007)
Narrative review: Fabry disease
Joe T. R. Clarke
ANNALS OF INTERNAL MEDICINE (2007)
Agalsidase-beta therapy for advanced Fabry disease - A randomized trial
Maryam Banikazemi et al.
ANNALS OF INTERNAL MEDICINE (2007)
Enzyme replacement therapy with agalsidase alfa in children with Fabry disease
U. Ramaswami et al.
ACTA PAEDIATRICA (2007)
Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life
Raymond Y. Wang et al.
GENETICS IN MEDICINE (2007)
Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease
L. B. Jardim et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2006)
White matter lesions in Fabry disease before and after enzyme replacement therapy - A 2-year follow-up
Laura B. Jardim et al.
ARQUIVOS DE NEURO-PSIQUIATRIA (2006)
Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey
D. Hajioff et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2006)
Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease
Markus Ries et al.
PEDIATRICS (2006)
Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease
Gregory Bierer et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2006)
Enzyme replacement therapy and intraepidermal innervation density in Fabry disease
Raphael Schiffmann et al.
MUSCLE & NERVE (2006)
Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease
Natalie Jansen Street et al.
GENETICS IN MEDICINE (2006)
Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy
Meinrad Beer et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Clinical benefit of enzyme replacement therapy in Fabry disease
F Breunig et al.
KIDNEY INTERNATIONAL (2006)
Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with α galactosidase A
PM Elliott et al.
HEART (2006)
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting
R Schiffmann et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2006)
The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease
RJ Kalliokoski et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2006)
Clinical manifestations of Fabry disease in children: Data from the Fabry outcome survey
U Ramaswami et al.
ACTA PAEDIATRICA (2006)
Enzyme replacement therapy in Japanese Fabry disease patients: The results of a phase 2 bridging study
Y Eto et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2005)
Enzyme replacement therapy in Fabry disease patients undergoing dialysis: Effects on quality of life and organ involvement
A Pisani et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2005)
The variation of morphological and functional cardiac manifestation in Fabry disease:: potential implications for the time course of the disease
F Weidemann et al.
EUROPEAN HEART JOURNAL (2005)
Is globotriaosylceramide a useful biomarker in Fabry disease?
E Young et al.
ACTA PAEDIATRICA (2005)
Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey)
B Hoffmann et al.
JOURNAL OF MEDICAL GENETICS (2005)
Enzyme replacement therapy improves function of C-, Aδ-, and Aβ-nerve fibers in Fabry neuropathy
MJ Hilz et al.
NEUROLOGY (2004)
The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy
C Whybra et al.
CLINICAL GENETICS (2004)
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey
A Mehta et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
Enzyme replacement therapy with agalsidase β improves cardiac involvement in Fabry's disease
L Spinelli et al.
CLINICAL GENETICS (2004)
Long-term safety and efficacy of enzyme replacement therapy for Fabry disease
WR Wilcox et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta
GE Linthorst et al.
KIDNEY INTERNATIONAL (2004)
CNS involvement in Fabry disease: Clinical and imaging studies before and after 12 months of enzyme replacement therapy
L Jardim et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2004)
Relief of gastrointestinal symptoms under enzyme replacement therafpy in patients with Fabry disease
F Dehout et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2004)
Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease - A prospective strain rate imaging study
F Weidemann et al.
CIRCULATION (2003)
A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease
K Lee et al.
GLYCOBIOLOGY (2003)
Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease
R Schiffmann et al.
MUSCLE & NERVE (2003)
The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents
M Ries et al.
EUROPEAN JOURNAL OF PEDIATRICS (2003)
Hearing loss in Fabry disease: The effect of agalsidase alfa replacement therapy
D Hajioff et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2003)
Enzyme replacement therapy in heterozygous females with Fabry disease: Results of a phase IIIB study
F Baehner et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2003)
Quality of life of patients with Fabry disease
KF Gold et al.
QUALITY OF LIFE RESEARCH (2002)
Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement
DF Moore et al.
STROKE (2002)
Patients with Fabry disease on dialysis in the United States
R Thadhani et al.
KIDNEY INTERNATIONAL (2002)
Assessment of health-related quality-of-life in males with Anderson Fabry Disease before therapeutic intervention
AH Miners et al.
QUALITY OF LIFE RESEARCH (2002)
Anderson-Fabry disease:: Clinical manifestations of disease in female heterozygotes
C Whybra et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2001)
Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males
KD MacDermot et al.
JOURNAL OF MEDICAL GENETICS (2001)
Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease - Reversal by enzyme replacement therapy
DF Moore et al.
CIRCULATION (2001)
Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
CM Eng et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Enzyme replacement therapy in Fabry disease - A randomized controlled trial
R Schiffmann et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease
R Schiffmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
